Moderna fully enrolls phase 3 trial for COVID-19 vaccine candidate, with heavy emphasis on traditionally under-represented communities

Oct 22, 2020 - 02:45 PM
COVID19 Web Sized

Moderna Inc., today announced the completion of enrollment for its COVID-19 vaccine phase 3 trial.

The drug maker said that it has confirmed 30,000 participants for an efficacy study of mRNA-1273. Moderna and the National Institute of Allergy and Infectious Diseases developed the candidate, which generated a strong immune response in older adults during its phase 1 clinical trial.

Communities that have historically been under-represented in clinical research and are disproportionately impacted by COVID-19 have significant representation among the trial enrollees. Moderna said the study includes more than 11,000 participants from communities of color, representing 37% of the study population and similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or Latinx, and more than 3,000 participants who identify as Black or African American.

Related News Articles

Headline
CMS Administrator Oz and Deputy Administrator Brillman discuss agency’s focus on innovation, reducing waste
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
CDC releases report on flu, COVID-19 vaccination coverage for health care workers for 2024-25 respiratory season 
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
Study estimates more than 155,000 uncounted COVID-19 deaths occurred early during pandemic 
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
CDC report highlights low use of COVID-19 antivirals among people 65 and older 
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
FDA issues guidance on wellness products, clinical decision support software
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…